KDR and gastric cancer: VEGF receptor 2 (VEGFR2) is expressed by intratumoral Tregs, and VEGFA stimulation induced Treg proliferation in a preclinical model.120 We have shown that ramucirumab, an anti-VEGFR2 antibody, reduces the proliferation of eTregs in patients with gastric cancer.121 Thus, targeting the VEGFA-VEGFR2 axis might activate antitumor responses via reduction of Treg proliferation and infiltration in the TME.